-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Text|Pharmaceutical Mission Hills
On September 27, Corning Jerry announced the updated data of Phase 2 clinical study of KN046 combined with albumin paclitaxel/gemcitabine in the first-line treatment of advanced pancreatic ductal adenocarcinoma (PDAC) at the 2021 Chinese Clinical Oncology Association (CSCO) annual meeting ( Study number: KN046-IST-04)
KN046 is a PD-L1/CTLA-4 bispecific antibody independently developed by Corning Jereh.
KN046-IST-04 is a phase 2 clinical study initiated by researchers in China, enrolling patients with unresectable locally advanced or metastatic pancreatic ductal adenocarcinoma confirmed by histology or cytology
The data released at the CSCO annual meeting further confirmed that KN046 combined with albumin paclitaxel/gemcitabine has excellent efficacy in the first-line treatment of unresectable locally advanced or metastatic pancreatic ductal adenocarcinoma, and the objective response rate (ORR) is more than doubled compared with traditional chemotherapy.
As of May 26, 2021, a total of 29 patients have been enrolled, and 20 patients (69.
Among the 22 patients who received at least one tumor assessment, the complete response rate (CR) was 4.
In terms of safety, 29 patients entered the safety analysis data set.
The main investigator of the clinical trial, Professor Jin Gang from the First Affiliated Hospital of Naval Military Medical University (Shanghai Changhai Hospital), said: “Pancreatic cancer is one of the most malignant tumors of the digestive system, 90% to 95% of which are pancreatic ducts.
At present, KN046 has carried out nearly 20 clinical trials in different stages covering more than 10 types of tumors such as non-small cell lung cancer, thymic cancer, pancreatic cancer, liver cancer, esophageal squamous cancer, triple negative breast cancer, etc.
Reference materials:
[1] Corning Jerry updated the Phase II clinical study data of KN046 combined with chemotherapy in the first-line treatment of advanced pancreatic cancer at the CSCO conference.
